26 results
Search Results
2. Nutritional intervention and neurodevelopmental outcome in infants with suspected cerebral palsy: the Dolphin infant double-blind randomized controlled trial.
- Author
-
Andrew, Morag J., Montague‐Johnson, Christine, Laler, Karen, Baker, Bonny, Sullivan, Peter B., Parr, Jeremy R., Qi, Cathy, and Montague-Johnson, Christine
- Subjects
NEURODEVELOPMENTAL treatment for infants ,CEREBRAL palsy ,DOCOSAHEXAENOIC acid ,NUTRITION ,RANDOMIZED controlled trials ,CEREBRAL palsy treatment ,NUCLEOTIDES ,CHOLINE ,CHILD development ,COMPARATIVE studies ,DIET therapy ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,BLIND experiment ,DISEASE complications ,PSYCHOLOGY ,THERAPEUTICS - Abstract
Copyright of Developmental Medicine & Child Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
3. Efficacy of metacognitive training for depression as add‐on intervention for patients with depression in acute intensive psychiatric inpatient care: A randomized controlled trial.
- Author
-
Hauschildt, Marit, Arlt, Sönke, Moritz, Steffen, Yassari, Amir H., and Jelinek, Lena
- Subjects
THERAPEUTICS ,PILOT projects ,ATTITUDE (Psychology) ,EFFECT sizes (Statistics) ,MOTIVATION (Psychology) ,TREATMENT duration ,PATIENT satisfaction ,SEVERITY of illness index ,TREATMENT effectiveness ,PATIENTS' attitudes ,RANDOMIZED controlled trials ,COMPARATIVE studies ,PSYCHOLOGICAL tests ,NEUROPSYCHOLOGICAL tests ,PRE-tests & post-tests ,MENTAL depression ,CRITICAL care medicine ,STATISTICAL sampling ,COGNITIVE testing ,COGNITIVE therapy ,PSYCHIATRIC treatment ,LONGITUDINAL method ,EVALUATION - Abstract
Background: Metacognitive training for depression (D‐MCT) is a novel low‐intensity group training for economic treatment of depression. Previous studies demonstrate its efficacy in moderately depressed outpatients. The present study evaluated efficacy and patients' perspective of the D‐MCT in severely depressed psychiatric inpatients. Methods: In a randomized‐controlled trial, 75 individuals with a major depressive disorder (MDD) were allocated to D‐MCT versus euthymic therapy as add‐on (twice a week) to cognitive‐behavioural‐based (CBT) inpatient‐care. Depressive symptoms (HDRS, BDI), dysfunctional (meta)cognition (DAS, MCQ‐30) and subjective appraisal were assessed at baseline, 4 weeks (post) and 3 months (follow‐up). Results: Participants in both conditions showed a large decline in depression at post and follow‐up‐assessment. No superior add‐effect of D‐MCT versus active control emerged for depression severity on top of the inpatient care. However, among patients with a diagnosis of MDD with no (vs. at least one) comorbidity, D‐MCT participants showed a larger decline in depressive (meta‐)cognition at follow‐up with medium‐to‐large effect sizes. D‐MCT was evaluated as superior in overall appraisal, treatment preference, motivation and satisfaction. Limitations: The follow‐up time interval of 3 months may have been too short to detect long‐term effects. There is emerging evidence that modification of (meta)cognition unfolds its full effects only with time. Effects of CBT inpatient‐care on outcome parameters cannot be differentiated. Conclusions: Although D‐MCT as an add‐on was not superior in complete case analyses, results suggest greater benefit for patients with MDD and no comorbidity. D‐MCT proved feasible in acute‐psychiatric inpatient‐care and was highly accepted by patients. Future studies should investigate the role of modified (meta)cognition on long‐term treatment outcome, including dropout and relapse rates. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial.
- Author
-
Lintzeris, Nicholas, Ritter, Alison, Panjari, Mary, Clark, Nicolas, Kutin, Jozica, and Bammer, Gabriele
- Subjects
- *
METHADONE treatment programs , *THERAPEUTIC use of narcotics , *SUBSTANCE abuse , *HEALTH planning , *COMMUNITY health services , *BUPRENORPHINE , *COMPARATIVE studies , *COST effectiveness , *EMPLOYEE orientation , *RESEARCH methodology , *MEDICAL cooperation , *METHADONE hydrochloride , *NARCOTIC antagonists , *NARCOTICS , *HEALTH outcome assessment , *RESEARCH , *STATISTICAL sampling , *SUBSTANCE abuse treatment , *EVALUATION research , *RANDOMIZED controlled trials , *ECONOMICS , *THERAPEUTICS - Abstract
Buprenorphine was registered in Australia as a maintenance and detoxification agent for the management of opioid dependence in November, 2000, and became widely available in August, 2001. This paper provides an overview of key developments in the introduction of buprenorphine treatment in Australia, with an emphasis upon the delivery of services in community-based (primary care) settings. A central study in this work was the Buprenorphine Implementation Trial (BIT), a randomized, controlled trial comparing buprenorphine and methadone maintenance treatment delivered under naturalistic conditions by specialist and community-based service providers (general practitioners and community pharmacists) in 139 subjects across nineteen treatment sites. In addition to conventional patient outcome measures (treatment retention, drug use, psychosocial functioning, and cost effectiveness), the BIT study also involved the development and evaluation of clinical guidelines, training programs for clinicians, and client literature, which are described here. Integration of treatment systems (methadone with buprenorphine, specialist and primary-care programs) and factors thought to be important in the uptake of buprenorphine treatment in Australia since registration are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
5. What to train first: Balance or explosive strength? Impact on performance and intracortical inhibition.
- Author
-
Lauber, Benedikt, Gollhofer, Albert, and Taube, Wolfgang
- Subjects
THERAPEUTICS ,EVOKED potentials (Electrophysiology) ,FRONTAL lobe ,RESISTANCE training ,POSTURAL balance ,EXERCISE physiology ,RANDOMIZED controlled trials ,COMPARATIVE studies ,PRE-tests & post-tests ,MUSCLE strength ,ATHLETIC ability ,STATISTICAL sampling - Abstract
Explosive strength and balance training are commonly applied to enhance explosive strength and balance performance. Even though both training methods are frequently implemented, ordering effects have largely been neglected. Therefore, the present study aimed to investigate ordering effects of balance and explosive strength training on explosive strength and balance performance as well as changes in short‐interval intracortical inhibition (SICI). Two groups of subjects either participated in 4 weeks of balance training followed by 4 weeks of explosive strength training (BT‐ET) or vice versa (ET‐BT). Before, after 4 and 8 weeks, balance performance, as well as explosive strength, was tested. Additionally, SICI was tested during rest as well as during balance perturbations and explosive contractions. The results show a training specific increase in performance with an increase in balance control followed by an increase in explosive strength in the BT‐ET, while the ET‐BT increased its balance and explosive strength in the opposite order. There were no significant ordering effects. Both groups showed a significant decrease in SICI during the explosive contractions after the eight weeks of training. When SICI was tested during the balance perturbations, SICI initially increased after the first 4 weeks of training but returned to baseline until the end of the eight weeks. It is suggested that the decrease in SICI with prolonged training might show a disengagement of the motor cortex during the balance task. During the explosive contractions, the low SICI levels are beneficial to provide the necessary level of excitatory cortical drive. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial.
- Author
-
Bellad, MB, Hoffman, MK, Mallapur, AA, Charantimath, US, Katageri, GM, Ganachari, MS, Kavi, A, Ramdurg, UY, Bannale, SG, Revankar, AP, Sloan, NL, Kodkany, BS, Goudar, SS, Derman, RJ, Bellad, M B, Hoffman, M K, Mallapur, A A, Charantimath, U S, Katageri, G M, and Ganachari, M S
- Subjects
CLINDAMYCIN ,PREMATURE labor prevention ,PREGNANT women ,MISCARRIAGE ,STILLBIRTH ,ANTIBIOTICS ,BACTERIAL vaginitis ,COMMUNICABLE diseases ,COMPARATIVE studies ,GESTATIONAL age ,PREMATURE infants ,RESEARCH methodology ,MEDICAL cooperation ,MEDICALLY underserved areas ,ORAL drug administration ,PREGNANCY complications ,PRENATAL care ,RESEARCH ,RURAL population ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,DISEASE incidence ,BLIND experiment ,THERAPEUTICS ,PREVENTION - Abstract
Objective: To determine whether oral clindamycin reduces the risk of preterm birth (PTB) in women with abnormal vaginal microflora as evidenced by a vaginal pH ≥5.0.Design: Randomised double-blind placebo-controlled trial.Setting: Rural southern India.Population: Pregnant women with a singleton fetus between 13+0/7 weeks and 20+6/7 weeks.Methods: Pregnant women were recruited during prenatal visits in Karnataka, India, from October 2013 to July 2015. Women were required to have a singleton fetus between 13+0/7 weeks and 20+6/7 weeks and an elevated vaginal pH (≥5.0) by colorimetric assessment. Participants were randomised to either oral clindamycin 300 mg twice daily for 5 days or an identical-appearing placebo.Main Outcome Measures: The primary outcome was the incidence of PTB, defined as delivery before 37+0/7 weeks.Results: Of the 6476 screened women, 1727 women were randomised (block randomised in groups of six; clindamycin n = 866, placebo n = 861). The demographic, reproductive, and anthropomorphometric characteristics of the study groups were similar. Compliance was high, with over 94% of capsules being taken. The rate of PTB before 37 weeks was comparable between the two groups [clindamycin 115/826 (13.9%) versus placebo 111/806 (13.8%), between-group difference 0.2% (95% CI -3.2 to 3.5%, P = 0.93)], as was PTB at less than 34 weeks [clindamycin 40/826 (4.8%) versus placebo group 37/806 (4.6%), between-group difference 0.3% (95% CI -1.8 to 2.3%, P = 0.81)]. No differences were detected in the incidence of birthweight of<2500 g, <1500 g, miscarriage, stillbirth or neonatal death.Conclusion: In this setting, oral clindamycin did not decrease PTB among women with vaginal pH ≥5.0.Tweetable Abstract: Oral clindamycin between 13+0/7 and 20+6/7 weeks does not prevent preterm birth in women with a vaginal pH ≥5.0. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study.
- Author
-
Laufs, Ulrich, Griese‐Mammen, Nina, Krueger, Katrin, Wachter, Angelika, Anker, Stefan D., Koehler, Friedrich, Rettig‐Ewen, Volker, Botermann, Lea, Strauch, Dorothea, Trenk, Dietmar, Böhm, Michael, Schulz, Martin, Griese-Mammen, Nina, and Rettig-Ewen, Volker
- Subjects
HEART failure ,RANDOMIZED controlled trials ,HOSPITAL care ,OUTPATIENT medical care ,DRUG therapy ,ADRENERGIC beta blockers ,ACE inhibitors ,ANGIOTENSIN receptors ,COMBINATION drug therapy ,COMPARATIVE studies ,DRUGS ,INTERDISCIPLINARY education ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PATIENT compliance ,RESEARCH ,STATISTICAL sampling ,PILOT projects ,EVALUATION research ,TREATMENT effectiveness ,THERAPEUTICS - Abstract
We report the rationale and design of a community PHARMacy-based prospective randomized controlled interdisciplinary study for ambulatory patients with Chronic Heart Failure (PHARM-CHF) and results of its pilot study. The pilot study randomized 50 patients to a pharmacy-based intervention or usual care for 12 months. It demonstrated the feasibility of the design and showed reduced systolic blood pressure in the intervention group as indicator for improved medication adherence. The main study will randomize patients ≥60 years on stable pharmacotherapy including at least one diuretic and a history of heart failure hospitalization within 12 months. The intervention group will receive a medication review at baseline followed by regular dose dispensing of the medication, counselling regarding medication use and symptoms of heart failure. The control patients are unknown to the pharmacy and receive usual care. The primary efficacy endpoint is medication adherence, pre-specified as a significant difference of the proportion of days covered between the intervention and control group within 365 days following randomization using pharmacy claims data for three CHF medications (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists). The primary composite safety endpoint is days lost due to blindly adjudicated unplanned cardiovascular hospitalizations or death. Overall, 248 patients shall be randomized. The minimum follow-up is 12 months with an expected mean of 24 months. Based on the feasibility demonstrated in the pilot study, the randomized PHARM-CHF trial will test whether an interdisciplinary pharmacy-based intervention can safely improve medication adherence and will estimate the potential impact on clinical endpoints. ClinicalTrials.gov Identifier: NCT01692119. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. A Ketone Ester Drink Lowers Human Ghrelin and Appetite.
- Author
-
Stubbs, Brianna J., Cox, Pete J., Evans, Rhys D., Cyranka, Malgorzata, Clarke, Kieran, and de Wet, Heidi
- Subjects
KETONES ,GHRELIN ,WEIGHT loss ,DIET ,BLOOD sampling ,BEVERAGE analysis ,APPETITE ,CARBOXYLIC acids ,COMPARATIVE studies ,CROSSOVER trials ,HUNGER ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,BLIND experiment ,THERAPEUTICS - Abstract
Objective: The ketones d-β-hydroxybutyrate (BHB) and acetoacetate are elevated during prolonged fasting or during a "ketogenic" diet. Although weight loss on a ketogenic diet may be associated with decreased appetite and altered gut hormone levels, it is unknown whether such changes are caused by elevated blood ketones. This study investigated the effects of an exogenous ketone ester (KE) on appetite.Methods: Following an overnight fast, subjects with normal weight (n = 15) consumed 1.9 kcal/kg of KE, or isocaloric dextrose (DEXT), in drinks matched for volume, taste, tonicity, and color. Blood samples were analyzed for BHB, glucose, insulin, ghrelin, glucagon-like peptide 1 (GLP-1), and peptide tyrosine tyrosine (PYY), and a three-measure visual analogue scale was used to measure hunger, fullness, and desire to eat.Results: KE consumption increased blood BHB levels from 0.2 to 3.3 mM after 60 minutes. DEXT consumption increased plasma glucose levels between 30 and 60 minutes. Postprandial plasma insulin, ghrelin, GLP-1, and PYY levels were significantly lower 2 to 4 hours after KE consumption, compared with DEXT consumption. Temporally related to the observed suppression of ghrelin, reported hunger and desire to eat were also significantly suppressed 1.5 hours after consumption of KE, compared with consumption of DEXT.Conclusions: Increased blood ketone levels may directly suppress appetite, as KE drinks lowered plasma ghrelin levels, perceived hunger, and desire to eat. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. Effect of continuing care for people with cocaine dependence on criminal justice sentences.
- Author
-
Wimberly, Alexandra S., Hyatt, Jordan M., and McKay, James R.
- Subjects
SUBSTANCE-induced disorders ,LIFE care communities ,CRIMINAL justice system ,COCAINE ,LOGISTIC regression analysis ,CRIMINAL convictions ,THERAPEUTICS ,SUBSTANCE abuse & psychology ,SUBSTANCE abuse treatment ,COMPARATIVE studies ,CONTINUUM of care ,COUNSELING ,CRIMINOLOGY ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness - Abstract
While continuing care for substance use treatment has been associated with reduced involvement in the criminal justice system, much of this research lacks random assignment to continuing care and so is limited by self-selection bias. This study sought to determine the impact of adding telephone-based continuing care to intensive outpatient programs on criminal justice outcomes for people with cocaine dependence. In three continuing care studies, spanning 1998-2008, participants were randomly assigned to an intensive outpatient program or an intensive outpatient program plus a telephone-based continuing care intervention. Cocaine-dependent participants from these three studies were included in the analyses, with outcomes derived from a dataset of jurisdiction-wide criminal sentences from a state sentencing agency. Multiple logistic regression was employed to examine the odds of a criminal conviction occurring in the 4 years after enrollment in a continuing care study. The results showed that, controlling for a criminal sentence in the previous year, gender, age, and continuing care study, people with cocaine dependence randomized to an intensive outpatient program plus a telephone-based continuing care intervention had 54% lower odds (p = 0.05, odds ratio = 0.46, 95% CI: 0.20-1.02) of a criminal sentence in the 4 years after enrollment in the continuing care study, compared with those randomized to an intensive outpatient program alone. We can conclude that adding telephone monitoring and counseling to intensive outpatient programs is associated with fewer criminal convictions over a 4-year follow-up period compared with intensive outpatient programs alone. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Hesperidin Supplementation Alleviates Oxidative DNA Damage and Lipid Peroxidation in Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
- Author
-
Homayouni, Fatemeh, Haidari, Fatemeh, Hedayati, Mehdi, Zakerkish, Mehrnoosh, and Ahmadi, Kambiz
- Subjects
ANTIOXIDANT analysis ,FLAVANONES ,BLOOD sugar ,COMPARATIVE studies ,DIET ,DIETARY supplements ,DNA ,RESEARCH methodology ,MEDICAL cooperation ,LIPID peroxidation (Biology) ,TYPE 2 diabetes ,RESEARCH ,STATISTICAL sampling ,MALONDIALDEHYDE ,OXIDATIVE stress ,EVALUATION research ,RANDOMIZED controlled trials ,BLIND experiment ,DEOXYRIBONUCLEOSIDES ,THERAPEUTICS - Abstract
This study aimed to examine the effects of hesperidin supplement on the glycemic parameters, oxidative DNA damage, and lipid peroxidation in patients with type 2 diabetes. Sixty-four patients were randomly allocated to receive 500 mg/day hesperidin or placebo capsules for 6 weeks. Data on glycemic parameters, total antioxidant capacity (TAC), 8-hydroxydeoxyguanosine (8-OHDG), and malondialdehyde (MDA) were collected at the baseline and at the end of the study. In hesperidin group, TAC increased (0.74 ± 0.16 vs. 0.82 ± 0.18), while serum froctoseamin (5.79 ± 5.86 vs. 5.01 ± 4.95; p = 0.001), 8-OHDG (14.32 ± 6.4 vs. 11.00 ± 7.0; p = 0.000), and MDA (5.78 ± 1.76 vs. 4.60 ± 0.75; p = 0.000) decreased in comparison with the baseline values. There was a significant difference in percent change of TAC (13.35 ± 19.21 vs. 3.13 ± 10.02; p = 0.043), froctoseamin (-10.10 ± 16.84 vs. 4.27 ± 34.646), 8-OHDG (-25.11 ± 28.23 vs. 8.69 ± 35.41; p = 0.000), and MDA (-16.46 ± 18.04 vs. -1.82 ± 22.63; p = 0.007) between hesperidin and control groups following intervention in adjusted models. These results suggest that hesperidin may improve TAC and alleviate serum froctoseamin, 8-OHDG, and MDA levels in type 2 diabetes. Copyright © 2017 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Preventing the Progression of Intestinal Failure-Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipid.
- Author
-
Diamond, Ivan R., Grant, Robert C., Pencharz, Paul B., de Silva, Nicole, Feldman, Brian M., Fitzgerald, Peter, Sigalet, David, Dicken, Bryan, Turner, Justine, Marchand, Valerie, Ling, Simon C., Moore, Aideen M., Avitzur, Yaron, and Wales, Paul W.
- Subjects
INTESTINAL disease treatment ,LIVER disease treatment ,PHOSPHOLIPIDS ,SOY oil ,INTRAVENOUS fat emulsions ,EMULSIONS ,BILIRUBIN ,COMPARATIVE studies ,INTESTINES ,INTESTINAL diseases ,LIVER diseases ,RESEARCH methodology ,MEDICAL cooperation ,PARENTERAL feeding ,RESEARCH ,STATISTICAL sampling ,PILOT projects ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,DISEASE complications ,THERAPEUTICS - Abstract
Background: To examine whether SMOFlipid prevents progression of intestinal failure-associated liver disease (IFALD) in parenteral nutrition (PN)-dependent infants with early IFALD (conjugated bilirubin 17-50 µmol/L, 1-3 mg/dL).Study Design: Pilot multicenter blinded randomized controlled trial comparing SMOFlipid with Intralipid. Patients received the trial lipid for up to 12 weeks, unless they achieved full enteral tolerance sooner. The primary clinical outcome was the serum conjugated bilirubin.Results: Twenty-four infants (mean age, 6 weeks) participated in the trial (13 Intralipid and 11 SMOFlipid). At the time of trial enrollment, patients in both groups were receiving 90% of their calories by PN. Mean duration on trial was 8 weeks and did not differ according to treatment ( P = .99). At trial conclusion, patients who received SMOFlipid had a lower conjugated bilirubin than those who received Intralipid (mean difference, -59 µmol/L; P = .03). Patients receiving SMOFlipid were also more likely to have a decrease in serum conjugated bilirubin to 0 µmol/L than those in the Intralipid group over the entire observation period (hazard ratio, 10.6; 95%; P = .03). The time to achievement of full enteral tolerance did not differ statistically (hazard ratio, 1.3; P = .59) between the groups. There was no significant difference in safety outcomes between the groups.Conclusions: Compared with Intralipid, SMOFlipid reduces the risk of progressive IFALD in children with intestinal failure. This trial was registered at clinicaltrials.gov as NCT00793195. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Seven versus 10 days antibiotic therapy for culture-proven neonatal sepsis: A randomised controlled trial.
- Author
-
Rohatgi, Smriti, Dewan, Pooja, Faridi, Mohammad Moonis Akbar, Kumar, Ashwani, Malhotra, Rajeev Kumar, and Batra, Prerna
- Subjects
ANTIBIOTICS ,NEONATAL sepsis ,DRUG efficacy ,PERINATAL care ,HEALTH outcome assessment ,THERAPEUTICS ,COMPARATIVE studies ,DRUG administration ,DOSE-effect relationship in pharmacology ,INTRAVENOUS therapy ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,MICROBIAL sensitivity tests ,RESEARCH ,RISK assessment ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,SEVERITY of illness index ,HOSPITAL mortality - Abstract
Aim: Optimal duration of parenteral antibiotics for treating neonatal sepsis ranges from 7-14 days. We compared the efficacy of 7 versus 10 days duration of intravenous antibiotics for neonatal septicaemia.Methods: We randomised blood culture-proven septic neonates (≥32 weeks and birth weight ≥1.5 kg) to receive either 7 or 10 days duration of intravenous antibiotics. We followed up neonates upto 28 days after stopping antibiotics for treatment failure defined by reappearance of clinical sepsis with a blood culture growing the same organism as cultured earlier, or in the absence of a positive culture, the presence of C-reactive protein and as adjudicated by an expert committee.Results: A total of 132 neonates were randomised to receive either 7 (n = 66) or 10 (n = 66) days duration of antibiotic therapy. Out of 128 neonates (64 per group) followed up, two (one per group) were regarded as 'treatment failure', and two were labelled as fresh episodes of sepsis (both in 10-day group). The risk (95% confidence interval) for treatment failure in the 7-day group was (1.0 (0.064-15.644) was not significantly higher. Neonates in both groups had comparable need for oxygen, inotropic support and blood products, duration of oxygen therapy and time to attainment of full feeds. The duration of hospitalisation was significantly longer in the 10-day group.Conclusion: A 7-day course of intravenous antibiotics may be sufficient to treat neonatal sepsis with the advantage of shorter hospital stay, but a larger meta-analysis would be required to state this with a degree of certainty. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
13. Local Minocycline Effect on Inflammation and Clinical Attachment During Periodontal Maintenance: Randomized Clinical Trial.
- Author
-
Killeen, Amy C., Harn, Jennifer A., Erickson, Leah M., Yu, Fang, and Reinhardt, Richard A.
- Subjects
PERIODONTICS ,MINOCYCLINE ,INFLAMMATION ,PERIODONTAL pockets ,DENTAL scaling ,TOOTH root planing ,PERIODONTAL probe ,INTERLEUKIN-1 ,ANTIBIOTICS ,COMPARATIVE studies ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PERIODONTAL disease ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,THERAPEUTICS - Abstract
Background: Minocycline microspheres (MMs) are being used to treat residual inflamed periodontal pockets during periodontal maintenance therapy (PMT), but evidence for efficacy from randomized clinical trials is lacking. The purpose of this study is to evaluate the effect of MMs plus scaling and root planing (SRP) on these sites.Methods: Sixty patients with chronic periodontitis on 6-month PMT intervals to be followed for 1 year were randomized (51 completed the study) into two statistically similar groups, SRP + MM (aged 66.8 years) and SRP alone (aged 67 years), to treat a ≥5 mm posterior interproximal pocket during PMT with a history of bleeding on probing (BOP). Group treatments were applied to the site at baseline and 6 months. Clinical attachment levels (CALs; primary outcome), probing depths (PDs), plaque, and BOP also were recorded at baseline and 6 and 12 months. In addition, gingival crevicular fluid was analyzed for an inflammation index ratio of interleukin (IL)-1β/IL-1 receptor antagonist (ra) using enzyme-linked immunosorbent assays.Results: All clinical parameters improved significantly (P <0.005) from baseline in both groups with no differences between groups at any time point. CAL decreased 17% (0.9 ± 0.8 mm) and 13% (0.7 ± 0.9 mm) in SRP + MM and 11% (0.7 ± 1.1 mm) and 21% (1.2 ± 0.9 mm) in SRP at 6 and 12 months, respectively. The odds of having BOP decreased 90% (down to 38% of patients) and 95% (26%) in SRP + MM and 82% (42%) and 82% (41%) in SRP at 6 and 12 months, respectively. IL-1β/IL-1ra decreased a significant 61% (P = 0.009) only in SRP + MM at 6 months.Conclusions: SRP of inflamed moderate pockets during 6-month PMT, with or without MMs, improves CALs, along with PDs and BOP over a 1-year period. The use of MMs did not result in an additional benefit over SRP alone. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
14. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
- Author
-
Magnani, Giulia, Giugliano, Robert P., Ruff, Christian T., Murphy, Sabina A., Nordio, Francesco, Metra, Marco, Moccetti, Tiziano, Mitrovic, Veselin, Shi, Minggao, Mercuri, Michele, Antman, Elliott M., and Braunwald, Eugene
- Subjects
THIAZOLES ,WARFARIN ,DRUG therapy ,HEART failure treatment ,ATRIAL fibrillation treatment ,VITAMIN K ,DRUG efficacy ,MEDICATION safety ,THERAPEUTICS ,VITAMIN therapy ,ANTICOAGULANTS ,PYRIDINE ,STROKE prevention ,ATRIAL fibrillation ,COMPARATIVE studies ,HEART failure ,HEMORRHAGE ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICAL sampling ,STROKE ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PROPORTIONAL hazards models ,BLIND experiment ,DISEASE complications - Abstract
Aims: In the ENGAGE AF-TIMI 48 trial, edoxaban, a factor Xa inhibitor, was not found to be inferior to warfarin for the prevention of stroke or systemic embolic events (SEE) in patients with atrial fibrillation (AF) and was associated with significantly less bleeding. The higher-dose edoxaban regimen (HDER; 60 mg dose-reduced to 30 mg once daily) has been approved in various countries in Europe, the USA, and Japan. Among patients treated with vitamin K antagonists (VKAs), symptomatic heart failure (HF) is an independent risk factor for lower time-in-therapeutic range, which reduces the efficacy and safety of VKA therapy. We evaluated the efficacy and safety of edoxaban compared with warfarin across the spectrum of HF severity in the ENGAGE AF-TIMI 48 trial.Methods and Results: Of 14 071 patients randomized to well-controlled warfarin or the HDER, 5926 (42%) had no history of HF, 6344 (45%) were in New York Heart Association (NYHA) class I-II, and 1801 (13%) were in NYHA class III-IV. The efficacy of edoxaban compared with warfarin in preventing stroke/SEE was similar in patients without and with HF regardless of the severity of HF; [HDER vs. warfarin: No-HF: hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.69-1.11; NYHA class I-II: HR 0.88, 95% CI 0.69-1.12; NYHA class III-IV: HR 0.83, 95% CI 0.55-1.25; Pinteraction = 0.97]. Compared with warfarin, HDER was consistently associated with lower risk of major bleeding (No-HF: HR 0.82, 95% CI 0.68-0.99; NYHA class I-II: HR 0.79, 95% CI 0.65-0.96; NYHA class III-IV: HR 0.79, 95% CI 0.54-1.17; Pinteraction = 0.96).Conclusion: The relative efficacy and safety of HDER compared with well-managed warfarin in AF patients with HF were similar to those without HF. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
15. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
- Author
-
Hesketh, Paul J., Schnadig, Ian D., Schwartzberg, Lee S., Modiano, Manuel R., Jordan, Karin, Arora, Sujata, Powers, Dan, and Aapro, Matti
- Subjects
SUBSTANCE P receptors ,CARBOPLATIN ,CANCER chemotherapy ,CANCER treatment ,TACHYKININ receptors ,CYCLOPHOSPHAMIDE ,IMMUNOSUPPRESSIVE agents ,VOMITING prevention ,ANTINEOPLASTIC agents ,CHEMOPREVENTION ,COMPARATIVE studies ,RESEARCH methodology ,HYDROCARBONS ,MEDICAL cooperation ,NAUSEA ,NEUROTRANSMITTER receptors ,RESEARCH ,STATISTICAL sampling ,TUMORS ,VOMITING ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,CHEMICAL inhibitors ,DISEASE complications ,PREVENTION ,THERAPEUTICS - Abstract
Background: Rolapitant, a novel neurokinin-1 receptor antagonist, provided effective protection against chemotherapy-induced nausea and vomiting (CINV) in a randomized, double-blind phase 3 trial of patients receiving moderately emetogenic chemotherapy or an anthracycline and cyclophosphamide regimen. The current analysis explored the efficacy and safety of rolapitant in preventing CINV in a subgroup of patients receiving carboplatin.Methods: Patients were randomized 1:1 to receive oral rolapitant (180 mg) or a placebo 1 to 2 hours before chemotherapy administration; all patients received oral granisetron (2 mg) on days 1 to 3 and oral dexamethasone (20 mg) on day 1. A post hoc analysis examined the subgroup of patients receiving carboplatin in cycle 1. The efficacy endpoints were as follows: complete response (CR), no emesis, no nausea, no significant nausea, complete protection, time to first emesis or use of rescue medication, and no impact on daily life.Results: In the subgroup administered carboplatin-based chemotherapy (n = 401), a significantly higher proportion of patients in the rolapitant group versus the control group achieved a CR in the overall phase (0-120 hours; 80.2% vs 64.6%; P < .001) and in the delayed phase (>24-120 hours; 82.3% vs 65.6%; P < .001) after chemotherapy administration. Superior responses were also observed by the measures of no emesis, no nausea, and complete protection in the overall and delayed phases and by the time to first emesis or use of rescue medication. The incidence of treatment-emergent adverse events was similar for the rolapitant and control groups.Conclusions: Rolapitant provided superior CINV protection to patients receiving carboplatin-based chemotherapy in comparison with the control. These results support rolapitant use as part of the antiemetic regimen in carboplatin-treated patients. Cancer 2016;122:2418-2425. © 2016 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
16. Effectiveness of an alcohol-free essential oil-containing mouthwash in institutionalised elders receiving long-term care: a feasibility study.
- Author
-
Chalhoub, Elsy, Emami, Elham, Freijé, Maria, Kandelman, Daniel, Campese, Melanie, St‐Georges, Annie, Voyer, René, Rompré, Pierre, Barbeau, Jean, Leduc, Annie, and Durand, Robert
- Subjects
MOUTHWASHES ,ANTISEPTICS in dentistry ,ORAL hygiene products ,LONG-term health care ,MEDICAL care ,SICK people ,BACTERIA classification ,THERAPEUTIC use of essential oils ,SALIVA microbiology ,BACTERICIDES ,BACTERIA ,CANDIDA ,COMPARATIVE studies ,DEMOGRAPHY ,DENTAL plaque ,DENTIFRICES ,DENTURES ,ETHANOL ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL records ,RESEARCH ,STATISTICAL sampling ,TOOTH care & hygiene ,TOBACCO ,WATER ,PILOT projects ,EVALUATION research ,RANDOMIZED controlled trials ,THERAPEUTICS ,PREVENTION - Abstract
Objectives: To conduct a feasibility study on investigating the effectiveness of an alcohol-free essential oil mouthwash (AF-EOMW) to reduce plaque accumulation and oral pathogen levels in institutionalised elders receiving long-term care and to obtain preliminary results.Background: Although simple, cost-effective strategies to improve oral hygiene in seniors such as the use of mouthwashes have been shown to reduce the risks of respiratory diseases, little information is available on the feasibility of implementing these measures.Methods: Twenty-five elderly participants with significant loss of autonomy were initially recruited and divided into two groups. A test group rinsed with an AF-EOMW twice a day, and a control group rinsed with tap water. Data on demographic characteristics, dental history and tobacco use were collected from a questionnaire. Problems encountered during recruitment and data collection were documented. Plaque index, denture cleanliness and salivary levels of several pathogens were measured at three time points: baseline (T0 ), day 22 (T1 ) and day 45 (T2 ).Results: Eighteen participants completed the study. Several problems were encountered during recruitment and execution of the study protocol. No significant differences in clinical or microbiological measures were found between the test group and controls at three time points (p > 0.05).Conclusion: This pilot study shows that, if sufficient logistical and financial resources are available, it is feasible to conduct randomised clinical trials in a seniors' facility. The use of an AF-EOMW to improve oral hygiene in seniors was not found to be superior to tap water. However, larger controlled clinical studies are needed to confirm these results. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
17. Clinical and Microbiologic Evaluation of Scaling and Root Planing per Quadrant and One-Stage Full-Mouth Disinfection Associated With Azithromycin or Chlorhexidine: A Clinical Randomized Controlled Trial.
- Author
-
Fonseca, Douglas Campideli, Cortelli, José Roberto, Cortelli, Sheila Cavalca, Miranda Cota, Luís Otávio, Machado Costa, Lidiane Cristina, Moreira Castro, Marcos Vinicius, Oliveira Azevedo, Andréa Mara, and Costa, Fernando Oliveira
- Subjects
DENTAL scaling ,TOOTH root planing ,AZITHROMYCIN ,CHLORHEXIDINE ,RANDOMIZED controlled trials ,PERIODONTITIS ,POLYMERASE chain reaction ,PERIODONTAL probe ,BACTERICIDES ,COMPARATIVE studies ,GRAM-negative bacteria ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PERIODONTAL pockets ,PERIODONTICS ,RESEARCH ,STATISTICAL sampling ,STERILIZATION (Disinfection) ,EVALUATION research ,THERAPEUTICS - Abstract
Background: Conflicting data about the protocol of choice for non-surgical periodontal therapy with adjuvant use are still reported. This study aims to evaluate, through clinical and microbiologic parameters, the systemic use of azithromycin (AZ) and chlorhexidine (CHX) as adjuvants to non-surgical periodontal treatment performed by one-stage full-mouth disinfection (FMD) within 24 hours or conventional quadrant scaling (QS) in four weekly sections.Methods: In this randomized controlled trial, 85 patients diagnosed with chronic periodontitis underwent different treatment protocols, in six groups: three FMD groups and three QS groups, each with no adjuvants, with CHX, and with AZ. Clinical periodontal parameters were recorded, and total and quantitative bacterial counts of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, and Streptococcus oralis were measured with real-time polymerase chain reaction at baseline and 90 and 180 days after treatment.Results: In all groups, a significant reduction was observed in the percentage of periodontal diseased sites, gingival index, plaque index, and clinical attachment level gain at 90 days, demonstrating effectiveness of the treatment, independently of the adjuvant. The FMD with CHX group showed higher reduction in probing depth and percentage of periodontal diseases sites, as well as lower total bacterial count, than all the other groups at 180 days.Conclusions: The adjuvant use of AZ did not provide any significant benefit, independently of the treatment protocol. The adjuvant use of CHX showed a more expressive and significant improvement in clinical and microbiologic parameters, especially in the FMD protocol, followed by QS. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
18. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.
- Author
-
Anker, Stefan D., Kosiborod, Mikhail, Zannad, Faiez, Piña, Ileana L., McCullough, Peter A., Filippatos, Gerasimos, van der Meer, Peter, Ponikowski, Piotr, Rasmussen, Henrik S., Lavin, Philip T., Singh, Bhupinder, Yang, Alex, and Deedwania, Prakash
- Subjects
HEART failure patients ,CARDIOTONIC agents ,PHYSIOLOGICAL effects of potassium ,ZIRCONIUM compounds ,CYCLOSILICATES ,PHYSIOLOGICAL effects of sodium ,PLACEBOS ,RANDOMIZED controlled trials ,THERAPEUTICS ,SILICATES ,COMPARATIVE studies ,HEART failure ,RESEARCH methodology ,MEDICAL cooperation ,POTASSIUM ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,BLIND experiment ,HYPERKALEMIA - Abstract
Aims: Hyperkalaemia in heart failure patients limits use of cardioprotective renin-angiotensin-aldosterone system inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS-9) is a selective potassium ion trap, whose mechanism of action may allow for potassium binding in the upper gastrointestinal tract as early as the duodenum following oral administration. ZS-9 previously demonstrated the ability to reduce elevated potassium levels into the normal range, with a median time of normalization of 2.2 h and sustain normal potassium levels for 28 days in HARMONIZE--a Phase 3, double-blind, randomized, placebo-controlled trial. In the present study we evaluated management of serum potassium with daily ZS-9 over 28 days in heart failure patients from HARMONIZE, including those receiving RAASi therapies.Methods and Results: Heart failure patients with evidence of hyperkalaemia (serum potassium ≥5.1 mmol/L, n = 94) were treated with open-label ZS-9 for 48 h. Patients (n = 87; 60 receiving RAASi) who achieved normokalaemia (potassium 3.5-5.0 mmol/L) were randomized to daily ZS-9 (5, 10, or 15 g) or placebo for 28 days. Mean potassium and proportion of patients maintaining normokalaemia during days 8-29 post-randomization were evaluated. Despite RAASi doses being kept constant, patients on 5 g, 10 g, and 15 g ZS-9 maintained a lower potassium level (4.7 mmol/L, 4.5 mmol/L, and 4.4 mmol/L, respectively) than the placebo group (5.2 mmol/L; P<0.01 vs. each ZS-9 group); greater proportions of ZS-9 patients (83%, 89%, and 92%, respectively) maintained normokalaemia than placebo (40%; P < 0.01 vs. each ZS-9 group). The safety profile was consistent with previously reported overall study population.Conclusion: Compared with placebo, all three ZS-9 doses lowered potassium and effectively maintained normokalaemia for 28 days in heart failure patients without adjusting concomitant RAASi, while maintaining a safety profile consistent with the overall study population. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
19. Adjunctive Non-Surgical Therapy of Inflamed Periodontal Pockets During Maintenance Therapy Using Diode Laser: A Randomized Clinical Trial.
- Author
-
Nguyen, Naomi‐Trang, Byarlay, Matthew R., Reinhardt, Richard A., Marx, David B., Meinberg, Trudy A., and Kaldahl, Wayne B.
- Subjects
PERIODONTAL disease prevention ,LASER therapy ,COMBINED modality therapy ,COMPARATIVE studies ,DENTAL scaling ,EXUDATES & transudates ,INTERLEUKIN-1 ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PERIODONTAL disease ,PERIODONTAL pockets ,PERIODONTITIS ,RESEARCH ,STATISTICAL sampling ,TOOTH root planing ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,PREVENTION - Abstract
Background: Numerous studies have documented the clinical outcomes of laser therapy for untreated periodontitis, but very few have reported on lasers treating inflamed pockets during maintenance therapy. The aim of this study is to compare the effectiveness of scaling and root planing (SRP) plus the adjunctive use of diode laser therapy to SRP alone on changes in the clinical parameters of disease and on the gingival crevicular fluid (GCF) inflammatory mediator interleukin-1β (IL-1β) in patients receiving regular periodontal maintenance therapy.Methods: This single-masked and randomized, controlled, prospective study includes 22 patients receiving regular periodontal maintenance therapy who had one or more periodontal sites with a probing depth (PD) ≥ 5 mm with bleeding on probing (BOP). Fifty-six sites were treated with SRP and adjunctive laser therapy (SRP + L). Fifty-eight sites were treated with SRP alone. Clinical parameters, including PD, clinical attachment level (CAL), and BOP, and GCF IL-1β levels were measured immediately before treatment (baseline) and 3 months after treatment.Results: Sites treated with SRP + L and SRP alone resulted in statistically significant reductions in PD and BOP and gains in CAL. These changes were not significantly different between the two therapies. Similarly, differences in GCF IL-1β levels between SRP + L and SRP alone were not statistically significant.Conclusion: In periodontal maintenance patients, SRP + L did not enhance clinical outcomes compared to SRP alone in the treatment of inflamed sites with ≥ 5 mm PD. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
20. Smoking cessation in smokers who smoke menthol and non-menthol cigarettes.
- Author
-
Smith, Stevens S., Fiore, Michael C., and Baker, Timothy B.
- Subjects
BUPROPION ,BLACK people ,CHI-squared test ,COMPARATIVE studies ,CONFIDENCE intervals ,LONGITUDINAL method ,HEALTH outcome assessment ,QUESTIONNAIRES ,RACE ,RESEARCH funding ,STATISTICAL sampling ,SEX distribution ,SMOKING cessation ,T-test (Statistics) ,TOBACCO ,WHITE people ,SECONDARY analysis ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,DATA analysis software ,DESCRIPTIVE statistics ,NICOTINE replacement therapy ,ODDS ratio ,THERAPEUTICS - Abstract
Aims To assess the relations of menthol cigarette use with measures of cessation success in a large comparative effectiveness trial ( CET). Design Participants were randomized to one of six medication treatment conditions in a randomized double-blind, placebo-controlled clinical trial. All participants received six individual counseling sessions. Setting Community-based smokers in two communities in Wisconsin, USA. Participants A total of 1504 adult smokers who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking. The analysis sample comprised 1439 participants: 814 white non-menthol smokers, 439 white menthol smokers and 186 African American ( AA) menthol smokers. There were too few AA non-menthol smokers ( n = 16) to be included in the analyses. Interventions Nicotine lozenge, nicotine patch, bupropion sustained release, nicotine patch + nicotine lozenge, bupropion + nicotine lozenge and placebo. Measurements Biochemically confirmed 7-day point-prevalence abstinence assessed at 4, 8 and 26 weeks post-quit. Findings In longitudinal abstinence analyses (generalized estimating equations) controlling for cessation treatment, menthol smoking was associated with reduced likelihood of smoking cessation success relative to non-menthol smoking [model-based estimates of abstinence = 31 versus 38%, respectively; odds ratio ( OR) = 0.71, 95% confidence interval ( CI) = 0.59, 0.86]. In addition, among menthol smokers, AA women were at especially high risk of cessation failure relative to white women (estimated abstinence = 17 versus 35%, respectively; OR = 2.63, 95% CI = 1.75, 3.96; estimated abstinence rates for AA males and white males were both 30%, OR = 1.06, 95% CI = 0.60, 1.66). Conclusion In the United States, smoking menthol cigarettes appears to be associated with reduced cessation success compared with non-menthol smoking, especially in African American females. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
- Author
-
Davies, M., Pratley, R., Hammer, M., Thomsen, A. B., and Cuddihy, R.
- Subjects
SUBCUTANEOUS injections ,ANALYSIS of covariance ,BLOOD sugar ,COMBINATION drug therapy ,COMPARATIVE studies ,DIABETES ,ENZYME inhibitors ,GLUCAGON ,GLYCOSYLATED hemoglobin ,HYPOGLYCEMIC agents ,METABOLIC regulation ,HEALTH outcome assessment ,PATIENT satisfaction ,STATISTICAL sampling ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,METFORMIN ,DRUG dosage ,THERAPEUTICS - Abstract
Aims Patient-reported outcomes from clinical trials offer insight into the impact of disease on health-related quality of life, including treatment satisfaction. This patient-reported outcomes evaluation was a substudy of a 26-week randomized, open label trial comparing the once-daily injectable human GLP-1 analogue liraglutide with once-daily oral sitagliptin, both added to metformin. The patient reported outcomes substudy aimed to evaluate treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at baseline and 26 weeks. Methods In themain 26-week randomized, open-label study (n = 658), liraglutide, 1.2 or 1.8 mg, injected with a pen, led to greater HbA1c reduction than oral sitagliptin, 100 mg once daily, both added to metformin = 1500 mg daily: mean HbA1c reduction was 1.5, 1.2 and 0.9% (7, 10 and 14 mmol/ mol) for liraglutide 1.8 mg, 1.2 mg and sitagliptin, respectively (P < 0.0001 for both liraglutide doses vs. sitagliptin) and liraglutide patients lost more weight (3 vs.1 kg; P < 0.0001). In this patient-reported outcomes substudy (liraglutide 1.8 mg, n = 171; 1.2 mg, n = 164; sitagliptin, n = 170) DTSQ scores were analyzed by ANCOVA with treatment and country as fixed effects and baseline value as covariate. Results Overall treatment satisfaction, calculated by adding satisfaction scores for 'current treatment', 'convenience', 'flexibility', 'understanding', 'recommend', and 'continue', improved in all groups at 26 weeks; greater improvement with liraglutide (4.35 and 3.51 vs. 2.96; P = 0.03 for liraglutide 1.8 mg vs. sitagliptin) may reflect greater HbA1c reduction and weight loss. Patients perceived themselves to be hyperglycaemic significantly less frequently with liraglutide 1.8 mg (difference = )0.88; P < 0.0001) and 1.2 mg(difference = )0.49; P = 0.01). Perceived frequency of hypoglycaemiawas similar across all groups. Conclusions Injectable liraglutide may lead to greater treatment satisfaction than oral sitagliptin, potentially by facilitating greater improvement in glycaemic control, weight loss and/ or perception of greater treatment efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
22. Administration of 400μg of misoprostol to augment routine active management of the third stage of labor
- Author
-
Hofmeyr, G. Justus, Fawole, Bukola, Mugerwa, Kidza, Godi, N. Patrick, Blignaut, Quentin, Mangesi, Lindeka, Singata, Mandisa, Brady, Leanne, and Blum, Jennifer
- Subjects
MISOPROSTOL ,DRUG administration ,DRUG efficacy ,MEDICATION safety ,THIRD trimester of pregnancy ,LABOR (Obstetrics) ,PROSTAGLANDINS ,HEMORRHAGE prevention ,PUERPERAL disorders ,COMPARATIVE studies ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,OXYTOCICS ,SUBLINGUAL drug administration ,PREVENTION ,THERAPEUTICS - Abstract
Abstract: Objective: To assess the effectiveness and safety of the administration of misoprostol, an orally active prostaglandin, in addition to routine uterotonic therapy as part of the active management of the third stage of labor. Methods: The present study was a hospital-based, decentralized, multi-center, randomized, placebo-controlled, double-blind trial. We enrolled 1103 women (out of a target sample size of 1180) at 4 hospitals in South Africa, Uganda, and Nigeria. Participants received a sublingual dose of 400μg of misoprostol or a placebo, in addition to standard active management of the third stage of labor, after vaginal birth. Results: The baseline characteristics of the participants were comparable. The difference in the primary outcome of blood loss of 500mL or more within 1 hour of randomization was not significant between the 2 groups (misoprostol 22/546 [4.0%] versus placebo 35/553 [6.3%]; relative risk, 0.64; 95% confidence interval, 0.38–1.07). Shivering and pyrexia occurred more frequently in the misoprostol group. No maternal deaths occurred. Conclusion: The present study did not confirm a beneficial effect of administering 400μg of misoprostol, in addition to routine uterotonic therapy, during the third stage of labor, but was consistent with other trials showing a cumulative modest benefit. Where routine uterotonics are available for prophylactic use, any potential benefit of misoprostol might not outweigh the likelihood of adverse effects. Trial registered on clinical trials.gov: NCT 00124540. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
23. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
- Author
-
Constantinescu, Gabriella, Theodoros, Deborah, Russell, Trevor, Ward, Elizabeth, Wilson, Stephen, and Wootton, Richard
- Subjects
VOICE disorder treatment ,SPEECH therapy methodology ,HYPOKINETIC dysarthria ,ANALYSIS of variance ,COMPARATIVE studies ,COMPUTERS in education ,ONLINE information services ,HEALTH outcome assessment ,PARKINSON'S disease ,PATIENT satisfaction ,RESEARCH evaluation ,RESEARCH funding ,STATISTICAL sampling ,SPEECH evaluation ,PHYSIOLOGICAL aspects of speech ,STATISTICS ,TELEMEDICINE ,VIDEOCONFERENCING ,HUMAN voice ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PRE-tests & post-tests ,INTER-observer reliability ,THERAPEUTICS - Abstract
Background: Telerehabilitation may be a feasible solution to the current problems faced by people with Parkinson's disease in accessing speech pathology services. Aim: To investigate the validity and reliability of online delivery of the Lee Silverman Voice Treatment (LSVT
® ) for the speech and voice disorder associated with Parkinson's disease. Method & Procedures: Thirty-four participants with Parkinson's disease and mild-to-moderate hypokinetic dysarthria took part in the randomized controlled non-inferiority laboratory trial and received the LSVT® in either the online or the face-to-face environment. Online sessions were conducted via two personal computer-based videoconferencing systems with real-time and store-and-forward capabilities operating on a 128 kbit/s Internet connection. Participants were assessed pre- and post-treatment on acoustic measures of mean vocal sound pressure level, phonation time, maximum fundamental frequency range, and perceptual measures of voice, articulatory precision and speech intelligibility. Outcomes & Results: Non-inferiority of the online LSVT® modality was confirmed for the primary outcome measure of mean change in sound pressure level on a monologue task. Additionally, non-significant main effects for the LSVT® environment, dysarthria severity, and interaction effects were obtained for all outcomes measures. Significant improvements following the LSVT® were also noted on the majority of measures. The LSVT® was successfully delivered online, although some networking difficulties were encountered on a few occasions. High participant satisfaction was reported overall. Conclusions & Implications: Online treatment for hypokinetic dysarthria associated with Parkinson's disease appears to be clinically valid and reliable. Suggestions for future research are outlined. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
24. Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis
- Author
-
Marcone, Valentina, Rocca, Giuseppe, Lichtner, Miriam, and Calzolari, Ettore
- Subjects
BACTERIAL vaginitis treatment ,LACTOBACILLUS ,VAGINITIS ,METRONIDAZOLE ,DISEASE relapse ,VAGINAL medication ,DIAGNOSIS ,ANTI-infective agents ,ALTERNATIVE medicine ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,ORAL drug administration ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,PROBIOTICS ,THERAPEUTICS - Abstract
Objective: To investigate the advantages of long-term vaginal administration of Lactobacillus rhamnosus after oral treatment with metronidazole to prevent the recurrence of bacterial vaginosis (BV).Methods: A total of 49 women with a diagnosis of BV were randomized into 2 groups. Group A was treated with a twice daily dose of 500 mg oral metronidazole for 7 days. Group B was treated with the same schedule followed by a once-weekly vaginal application of 40 mg of Lactobacillus rhamnosus for 6 months. A non-parametric analysis of variance for repeated measures was used to test whether there were significant changes in the vaginal ecosystems in the 2 groups.Results: During the first 6 months of follow-up, a constant percentage (96%) of patients in group B had a balanced vaginal ecosystem. Follow-up over 12 months showed no statistically significant difference among vaginal ecosystems in patients in group B (P=0.40), whereas in group A there was a significant increase in the number of women with abnormal flora over time (P=0.01).Conclusion: The vaginal administration of the probiotic Lactobacillus rhamnosus allows stabilization of the vaginal ecosystem and reduces the recurrence of BV. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
25. Controlling postpartum hemorrhage after home births in Tanzania
- Author
-
Prata, N., Mbaruku, G., Campbell, M., Potts, M., and Vahidnia, F.
- Subjects
HEMORRHAGE ,ARTERIAL injuries ,THERAPEUTICS ,HEMORRHAGE prevention ,PUERPERAL disorders ,CHILDBIRTH at home ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL referrals ,MEDICALLY underserved areas ,RECTAL medication ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,MISOPROSTOL ,OXYTOCICS ,PREVENTION - Abstract
Objectives: Determine safety of household management of postpartum hemorrhage (PPH) with 1000 microg of rectal misoprostol, and assess possible reduction in referrals and the need for additional interventions.Methods: Traditional birth attendants (TBAs) in Kigoma, Tanzania were trained to recognize PPH (500 ml of blood loss). Blood loss measurement was standardized by using a local garment, the "kanga". TBAs in the intervention area gave 1000 microg of misoprostol rectally when PPH occurred. Those in the non-intervention area referred the women to the nearest facility.Results: 454 women in the intervention and 395 in the non-intervention areas were eligible. 111 in the intervention area and 73 in the non-intervention had PPH. Fewer than 2% of the PPH women in the intervention area were referred, compared with 19% in the non-intervention.Conclusion: Misoprostol is a low cost, easy to use technology that can control PPH even without a medically trained attendant. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
26. Pergolide mesylate for cocaine abuse: a controlled preliminary trial.
- Author
-
Levin, Frances R., McDowell, David, Evans, Suzette M., Brooks, Daniel, Spano, Christina, Nunes, Edward V., Levin, F R, McDowell, D, Evans, S M, Brooks, D, Spano, C, and Nunes, E V
- Subjects
DRUG abuse treatment ,COCAINE ,RISPERIDONE ,DOPAMINE agonists ,DOPAMINE antagonists ,SUBSTANCE abuse diagnosis ,ERGOT alkaloids ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,PSYCHOLOGICAL tests ,RESEARCH ,RESEARCH funding ,STATISTICAL sampling ,SUBSTANCE abuse ,TIME ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,THERAPEUTICS - Abstract
A small, controlled study was conducted to assess whether pergolide mesylate has clinical promise as a treatment for cocaine abuse prior to embarking on a larger, randomized, double-blind, controlled trial. Fourteen individuals were placed on placebo for 2 weeks, followed by a 24-week single-blind study in which they were placed on pergolide for 12 weeks, followed by placebo for 12 weeks. Another 14 patients received single-blind placebo for two weeks and then were randomized into a 24-week double-blind, placebo-controlled, multiple baseline design. Initially, patients enrolled in the study were placed on risperidone (n = 9) or placebo (n = 5). During the first 12 weeks, retention was worse for those receiving pergolide compared to risperidone or placebo. Neither risperidone nor pergolide were more efficacious in reducing cocaine use than placebo. Although earlier open studies found pergolide to show promise as a treatment for cocaine abuse, this study did not support these earlier findings. Comparing an agent to both an active control and placebo group may better predict whether a promising new agent will have clinical utility compared to the standard open trial. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.